Published in Law and Health Weekly, January 21st, 2006
There is currently no formulation of this type approved for use in North America.
Under the terms of this agreement, Wyeth Consumer Healthcare will pay Scolr Pharma an upfront licensing fee, and will make milestone and royalty payments. The license agreement also contemplates further arrangements between Scolr Pharma and Wyeth Consumer Healthcare...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.